BioSpace News Archive

Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported financial results for the first quarter 2022 and provided a corporate update.

Exelixis, Inc. reported financial results for the first quarter of 2022 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.

Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

OraSure Technologies, Inc. announced its financial results for the three months ended March 31, 2022.

Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines, reported financial results and business highlights for the first quarter 2022.

Talis Biomedical Corporation reported financial results for the first quarter ended March 31, 2022.

Crinetics Pharmaceuticals, Inc. announced that on May 10, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 234,600 shares of its common stock to eight new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.

Mozart Therapeutics , a leading developer of CD8 Treg modulators in autoimmune and inflammatory disease, today announced the presentation of data at the American Association of Immunologists (AAI) Annual Meeting.

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of four new patents, two in the U.S. and two in China.

Quanterix reports continued revenue growth as it scales to support transformational advances in neurology research.